The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities
Open accessAbstract
Objectives: Diabetes mellitus is characterised by progressive β-cell destruction and loss of function, or loss of ability of tissues to respond to insulin. Daily subcutaneous insulin injection is standard management for people with diabetes, although patient compliance is hard to achieve due to the inconvenience of injections, so other forms of delivery are being tested, including oral administration. This review summarises the developments in oral insulin administration. Methods: The PubMed database was consulted to compile this review comparing conventional subcutaneous injection of insulin to the desired oral delivery. Key findings: Oral administration of insulin has potential benefits in reducing pain and chances of skin infection, improving the portal levels of insulin and avoiding side effects such as hyperinsulinemia, weight gain and hypoglycaemia. Although oral delivery of insulin is an ideal administration route for patients with diabetes, several physiological barriers have to be overcome. An expected low oral bioavailability can be attributed to its high molecular weight, susceptibility to enzymatic proteolysis and low diffusion rate across the mucin barrier. Conclusions: Strategies for increasing the bioavailability of oral insulin include the use of enzyme inhibitors, absorption enhancers, mucoadhesive polymers and chemical modification for endogenous receptor-mediated absorption. These may help significantly increase patient compliance and disease management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“Obesity is one of the risk factors that is associated with a higher degree of insulin resistance.([9]) For children in certain ethnic groups such as African Americans, Hispanics, Asians, Islanders and American Indians, there is an increasing prevalence of T2DM.”
BackgroundGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 2×
“It is estimated that the number of cases will increase to 592 million over the next 20 years.([12]) India, China and the United States will have the highest number of patients suffering from diabetes.”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
(2) Classification and diagnosis of diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s005 · Cited by 1,841
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022
Approaches for enhancing oral bioavailability of peptides and proteins
Renukuntla, J., Vadlapudi, A. D., Patel, A., Boddu, S. H. S., & Mitra, A. K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.030 · Cited by 681 · cited 1×
“Ideal properties of permeation enhancers include non-toxicity, pharmacologically and chemically inertness, non-irritating and non-allergenic.([77]) Other novel oral insulin absorption enhancers include zonula occluden toxin (ZOT is secreted by Vibrio cholera).”
BackgroundCorrelates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407
Andrews, R., Cooper, A., Montgomery, A., Norcross, A., Peters, T., Sharp, D., Jackson, N., Fitzsimons, K., Bright, J., Coulman, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60442-x · Cited by 302
Purnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
Liu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180 · cited 1×
“These drugs are employed to lower the glycation of HbA1c, improve insulin secretion and reduce resistance to insulin.([28]) Insulin may be required in the following special circumstances if there is evidence of oral combination medication failure after 3–6 months, the initial HbA1c is elevated (≥9.”
BackgroundInsulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia
Choudhary, P., Shin, J., Wang, Y., Evans, M. L., Hammond, P. J., Kerr, D., Shaw, J. A. M., Pickup, J. C., & Amiel, S. A. (2011) · Diabetes Care · doi:10.2337/dc10-2411 · Cited by 175
Binkley, N., Bolognese, M., Sidorowicz-Bialynicka, A., Vally, T., Trout, R., Miller, C., Buben, C. E., Gilligan, J. P., Krause, D. S., & for the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1602 · Cited by 149 · cited 1×
“Citric acid is added to the tablet core to inhibit intestinal proteases and enhance paracellular transport.([69]) The use of this approach has the potential to facilitate the oral delivery of other peptide-based drugs such as insulin.”
Background
Cited by
Ionic liquids for oral insulin delivery
Banerjee, A., Ibsen, K., Brown, T., Chen, R., Agatemor, C., & Mitragotri, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722338115 · Cited by 378
Oral delivery of proteins and peptides: Challenges, status quo and future perspectives
Zhu, Q., Chen, Z., Paul, P. K., Lu, Y., Wu, W., & Qi, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.001 · Cited by 353
Wong, C. Y., Al-Salami, H., & Dass, C. R. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.036 · Cited by 269
Self-citationPotential of insulin nanoparticle formulations for oral delivery and diabetes treatment.
Wong, C. Y., Al-Salami, H., & Dass, C. R. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.003 · Cited by 257
Self-citationEnteric coating of oral solid dosage forms as a tool to improve drug bioavailability
Maderuelo, C., Lanao, J. M., & Zarzuelo, A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105019 · Cited by 147
Metadata
- Authors
- Wong, C. Y., Martinez, J., & Dass, C. R.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09-01
- Volume
- 68
- Issue
- 9
- Pages
- 1093-1108
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W2472538305
- Cited by
- 183
- References
- 13
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.